Travere Therapeutics (NASDAQ:TVTX) PT Raised to $16.00

Travere Therapeutics (NASDAQ:TVTX) had its price target increased by Wedbush from $13.00 to $16.00 in a research report sent to investors on Friday morning, Benzinga reports. Wedbush currently has an outperform rating on the stock.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a buy rating and issued a $19.00 price target on shares of Travere Therapeutics in a report on Tuesday, May 7th. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $15.18.

Travere Therapeutics Stock Down 2.6 %

Shares of Travere Therapeutics stock opened at $9.00 on Friday. Travere Therapeutics has a one year low of $5.12 and a one year high of $16.79. The company has a market cap of $685.17 million, a P/E ratio of -4.29 and a beta of 0.77. The company has a debt-to-equity ratio of 5.10, a quick ratio of 2.75 and a current ratio of 2.78. The firm has a fifty day moving average of $8.36 and a two-hundred day moving average of $7.76.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 207.40%. Travere Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.27) EPS. On average, analysts forecast that Travere Therapeutics will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TVTX. ProShare Advisors LLC increased its holdings in shares of Travere Therapeutics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after buying an additional 1,557 shares during the last quarter. Arizona State Retirement System increased its stake in Travere Therapeutics by 9.7% during the fourth quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock worth $189,000 after acquiring an additional 1,851 shares during the last quarter. Signaturefd LLC increased its stake in Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock worth $27,000 after acquiring an additional 2,849 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Travere Therapeutics by 10.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock valued at $240,000 after purchasing an additional 2,948 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Travere Therapeutics by 7.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock worth $417,000 after purchasing an additional 3,083 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.